In this video interview, incoming Argenx CEO Karen Massey explains how the European biotech generates $4 billion in annual revenue with fewer than 2,000 employees ' and describes the organizational model that makes it possible. Biotech companies face the same dilemma as businesses in other industries: Innovation drops off dramatically with scale. European biotech Argenx has reached a market value of more than $40 billion, having so far escaped that innovation trap. How has it done this' The company shuns hierarchy and instead organizes into small teams, each dedicated to fighting a single disease with a laser focus on bringing value to the patient. Listen as hosts Kate W. Isaacs and Michele Zanini dig into the details of how Argenx uses distributed leadership to maintain its innovative edge and uncover insights that you can apply in your own organization.
learn more
